Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects.
暂无分享,去创建一个
[1] S. Mudaliar,et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. , 1999, Diabetes care.
[2] A. Lindholm,et al. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. , 1999, Diabetes care.
[3] I. Gonda,et al. Design and testing of aerosol delivery systems for reproducible clinical performance. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[4] A. McElduff,et al. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. , 2000, Diabetes technology & therapeutics.
[5] R J Roberts,et al. Human insulin. , 1984, Iowa medicine : journal of the Iowa Medical Society.
[6] L. Vignati,et al. Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment , 1997, Diabetes.
[7] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[8] L. Heinemann,et al. Time–action Profile of Inhaled Insulin , 1997, Diabetic medicine : a journal of the British Diabetic Association.
[9] P. Wollmer,et al. Quantitative evaluation of aerosol deposition pattern in the lung in patients with chronic bronchitis. , 1994, Physiological measurement.
[10] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[11] D. Owens,et al. Human Insulin: Clinical Pharmacological Studies in Normal Man , 1986 .
[12] R M Gardner,et al. Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.
[13] L. Vignati,et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. , 1997 .
[14] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[15] T. Isawa,et al. Effect of bronchodilation on the deposition and clearance of radioaerosol in bronchial asthma in remission. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] S J Farr,et al. Inhalation delivery systems with compliance and disease management capabilities. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[17] W. Bria,et al. Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients. , 1998, Chest.
[18] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[19] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[20] P. Brunetti,et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. , 1999, Diabetes care.
[21] A. Lindholm,et al. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Aspart , 2001, Clinical pharmacokinetics.
[22] W. Cefalu,et al. Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.
[23] E. Daviskas,et al. Deposition of aqueous aerosol of technetium-99m diethylene triamine penta-acetic acid generated and delivered by a novel system (AERx) in healthy subjects , 1999, European Journal of Nuclear Medicine.
[24] M. Trautmann,et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[25] W. Cefalu,et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.
[26] G. Bolli,et al. Insulin analogues and their potential in the management of diabetes mellitus , 1999, Diabetologia.
[27] R. Blouin,et al. In Vivo and In Vitro β2‐Adrenergic Receptor Responsiveness in Young and Elderly Asthmatics , 1992, Pharmacotherapy.
[28] Jeff Schuster,et al. The AERX™ Aerosol Delivery System , 1997, Pharmaceutical Research.
[29] M. Ellmerer,et al. Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients , 2001, Diabetologia.
[30] R. Ahrens,et al. Albuterol: An Adrenergic Agent for Use in the Treatment of Asthma Pharmacology, Pharmacokinetics and Clinical Use , 1984, Pharmacotherapy.
[31] D. Howey,et al. Comparative Pharmacokinetics and Glucodynamics of Two Human Insulin Mixtures 70/30 and 50/50 insulin mixtures , 1994, Diabetes Care.